Search all trials

Find therapies in clinical trials near you

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Factor IX deficiency+1

Recruiting

InvestigationalNo placebo

A study on the long-term safety and effectiveness of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B

InvestigationalNo placebo

France

Participants:18–64 years
Substances:Fidanacogene Elaparvovec

Contact Research Centre

Factor IX deficiency

Recruiting

Registered drugNo placebo

Study of Etranacogene Dezaparvovec (CSL222) in Adolescent Males with Severe or Moderately Severe Hemophilia B

Registered drugNo placebo

Austria

Participants:0–17 years
Substances:Etranacogene Dezaparvovec

Contact Research Centre

Factor IX deficiency

Recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Adults with Severe or Moderately Severe Hemophilia B and AAV5 Antibodies

Registered drugNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Etranacogene Dezaparvovec

Contact Research Centre

Factor IX deficiency

Recruiting

InvestigationalNo placebo

Study on the Safety and Effectiveness of REGV131 and LNP1265 for Adults with Hemophilia B

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Adeno-Associated Virus Vector Serotype 8 Containing The Human F9 Gene

Contact Research Centre

Factor IX deficiency+3

Recruiting

InvestigationalNo placebo

Study on the Effectiveness of Concizumab for Children Under 12 with Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo

Bulgaria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Concizumab

Contact Research Centre

Factor IX deficiency+1

Recruiting

InvestigationalNo placebo

Study on Long-Term Safety and Effects of Marstacimab for Patients with Severe Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Marstacimab

Contact Research Centre

Factor IX deficiency+1

Recruiting

InvestigationalNo placebo

Study on Marstacimab for Children with Severe Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo

Austria

Participants:0–17 years
Substances:Marstacimab

Contact Research Centre

Factor IX deficiency+1

Not yet recruiting

Registered drugNo placebo

Study on Joint Health in Hemophilia A and B Patients Using Efmoroctocog Alfa or Eftrenonacog Alfa

Registered drugNo placebo

Bulgaria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Efmoroctocog Alfa

Contact Research Centre

Factor IX deficiency

Not recruiting

Registered drugNo placebo

Title: Study of gene therapy Etranacogene Dezaparvovec (Hemgenix) in adult patients with moderate to severe Hemophilia B

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Etranacogene Dezaparvovec

Contact Research Centre

Factor IX deficiency+1

Not recruiting

InvestigationalNo placebo

Study on How Concizumab Works for Patients with Hemophilia A or B Without Inhibitors

InvestigationalNo placebo

Denmark

Participants:0–17 years · 18–64 years · 65+ years
Substances:Concizumab

Contact Research Centre

Factor IX deficiency

Not recruiting

Registered drugNo placebo

Long-term Safety Study of Etranacogene Dezaparvovec in Adult Men with Hemophilia B

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Etranacogene Dezaparvovec

Contact Research Centre

Factor IX deficiency

Not recruiting

Registered drugNo placebo

Study on Long-Term Safety and Efficacy of Etranacogene Dezaparvovec for Adults with Severe or Moderately Severe Hemophilia B

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Etranacogene Dezaparvovec

Contact Research Centre

Find therapies in clinical trials near you

13 trials match your criteria

Factor IX deficiency+1

A study on the long-term safety and effectiveness of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B

Factor IX deficiency

Study of Etranacogene Dezaparvovec (CSL222) in Adolescent Males with Severe or Moderately Severe Hemophilia B

Factor IX deficiency

Study on the Safety and Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Adults with Severe or Moderately Severe Hemophilia B and AAV5 Antibodies

Factor IX deficiency

Study on the Safety and Effectiveness of REGV131 and LNP1265 for Adults with Hemophilia B

Factor IX deficiency+3

Study on the Effectiveness of Concizumab for Children Under 12 with Hemophilia A or B, With or Without Inhibitors

Factor IX deficiency+1

Study on Long-Term Safety and Effects of Marstacimab for Patients with Severe Hemophilia A or B, With or Without Inhibitors

Factor IX deficiency+1

Study on Marstacimab for Children with Severe Hemophilia A or B, With or Without Inhibitors

Factor IX deficiency+1

Study on Joint Health in Hemophilia A and B Patients Using Efmoroctocog Alfa or Eftrenonacog Alfa

Factor IX deficiency

Title: Study of gene therapy Etranacogene Dezaparvovec (Hemgenix) in adult patients with moderate to severe Hemophilia B

Factor IX deficiency+1

Study on How Concizumab Works for Patients with Hemophilia A or B Without Inhibitors

Factor IX deficiency

Long-term Safety Study of Etranacogene Dezaparvovec in Adult Men with Hemophilia B

Factor IX deficiency

Study on Long-Term Safety and Efficacy of Etranacogene Dezaparvovec for Adults with Severe or Moderately Severe Hemophilia B

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.